A Systematic Review and Meta-Analysis of Bevacizumab in First-Line Metastatic Breast Cancer: Lessons for Research and Regulatory Enterprises

BACKGROUND: The US Food and Drug Administration’s accelerated approval and later withdrawal of bevacizumab in patients with metastatic breast cancer (mBC) is a seminal case for ongoing debates about the validity of using progression-free survival (PFS) as a surrogate measure for overall survival (OS...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Natl Cancer Inst
Main Authors: Hey, Spencer Phillips, Gyawali, Bishal, D’Andrea, Elvira, Kanagaraj, Manoj, Franklin, Jessica M, Kesselheim, Aaron S
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2019
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7156929/
https://ncbi.nlm.nih.gov/pubmed/31651981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djz211
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados